TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
ConditionIntrahepatic Cholangiocarcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorFudan University
About this trial
The objective of this study is to evaluate the efficacy and safety of TACE combined with Tislelizumab in patients with advanced intrahepatic cholangiocarcinoma after progression on first-line systemic therapy.
Eligibility criteria
Qualifiers
Written informed consent obtained.
Age ≥ 18 years at the time of study entry.
Participants must have unresectable or metastatic histologically or cytologically confirmed intrahepatic cholangiocarcinoma
Participants must have failed 1 line of systemic regimens for advanced cholangiocarcinoma due to disease progression or toxicity.
Disqualifiers
History of cardiac disease, including clinically significant gastrointestinal bleeding within 4 weeks prior to start of study treatment.
Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months Prior to the first dose of study drug with the exception of thrombosis of a segmental portal vein.
RFA and resection administered less then 4 weeks prior to study treatment start.
Radiotherapy administered less then 4 weeks prior to study treatment start.
Trial design
Treatments tested in this trial
- Tislelizumab
- TACE
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov